Intervet introduces Continuum Feline HCP vaccine with three-year immunity

Article

MILLSBORO, DEL. - Intervet Inc. announces the introduction of Continuum? Feline HCP vaccine with a three-year duration of immunity against rhinotracheitis caused by herpesvirus-1 (FHV-1), calicivirus (FCV) and panleukopenia (FPV).

MILLSBORO, DEL. — Intervet Inc. announces the introduction of Continuum® Feline HCP vaccine with a three-year duration of immunity against rhinotracheitis caused by herpesvirus-1 (FHV-1), calicivirus (FCV) and panleukopenia (FPV).

Continuum Feline HCP is the first feline vaccine approved for three-year protection against these diseases, according to the company.

This product provides flexibility to customize feline vaccination protocols, the company adds.

With a non-adjuvanted formulation, Continuum Feline HCP provides long-term safety for cats 8 weeks of age and older and may reduce the risk of adverse events, the company reports.

Study results included:

  • Rhinotracheitis: Statistically significant reduction in virulent FRV-associated clinical signs (P=0.005).

  • Calicivirus: 100 percent protection against oral ulcerations associated with FCV infection.

  • Panleukopenia: 100 percent protection against disease associated with virulent FPV challenge.

For fastest response, call

(800) 441-8272

www.continuum3.com

Newsletter

From exam room tips to practice management insights, get trusted veterinary news delivered straight to your inbox—subscribe to dvm360.

Recent Videos
Melissa Evans, CVT, LVT, VTS (ECC)
Meghan Herron, DVM, DACVB, FFCV
© 2025 MJH Life Sciences

All rights reserved.